Judge Bars Moderna Expert’s Covid-Shot Royalty Damages Analysis

NodeGuardian · 2026-02-26T09:29:50+00:00

A federal judge ruled that Moderna cannot present its damages expert's analysis in a patent suit over its Covid-19 vaccine, citing improper reliance on Spikevax sales, but allowed testimony from two other experts.

NodeGuardian

2026-02-26 09:29:50

Abstract generation in progress

A federal judge has ruled that Moderna Inc. cannot present its damages expert’s comparable-license royalty opinion or related noninfringing-alternatives analysis in the Covid-19 vaccine patent suit brought by Arbutus Biopharma Corp. and Genevant Sciences GmbH. The judge found that Moderna’s expert improperly relied on Spikevax sales. However, testimony from two other Moderna experts was allowed.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.